Cargando…
GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
Cardiovascular disease (CVD) remains the leading cause of death in patients with type 2 diabetes (T2D). Older age, prior heart failure (HF) and CV events, peripheral artery disease, and kidney complications can identify a subgroup of patients with T2D at high risk of mortality who are likely to achi...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513211/ https://www.ncbi.nlm.nih.gov/pubmed/34641876 http://dx.doi.org/10.1186/s12933-021-01400-9 |